## Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

Form 4	PHARMACEUT	TICALS I	INC								
May 08, 201:									OMB AF	PROVAL	
FORM	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287	
Check thi if no long subject to Section 1 Form 4 or Form 5	G. r	STATEMENT OF CHAN								stimated average Irden hours per	
obligation may cont <i>See</i> Instru 1(b).	ns Section 17(a	a) of the I	to Section 16(a) of the Securities Exchange Act of 1934, the Public Utility Holding Company Act of 1935 or Section (h) of the Investment Company Act of 1940						1		
(Print or Type R	Responses)										
Bishop John E Symbo MON PHA			Symbol MOME	IACEUT			ng	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		liddle) 2., 675	-	Earliest Tra ay/Year)	ansaction			Director X Officer (give below) Senior VP,		Owner er (specify l Scie	
(Street) 4. If Amer				ndment, Date Original nth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/D	n Date, if	3. Transactio Code (Instr. 8) Code V	4. Securi n(A) or Di (Instr. 3, Amount	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/06/2015			S <u>(1)</u>	493	D	\$ 19.05	111,485	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Titl Amou Under Securi (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu: Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Bishop John E C/O MOMENTA PHARMACEUTICALS, IN 675 WEST KENDALL STREET CAMBRIDGE, MA 02142	IC.		Senior VP, Pharmaceutical Scie				
Signatures							
/s/ Marie T. Washburn as attorney in fact	05/08/2015						
**Signature of Reporting Person	Date						
<b>Explanation of Responses</b>	s:						

## \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.